Answer
Hypertrophic cardiomyopathy (HCM) is a myocardial disorder that is often inherited, defined by left ventricular hypertrophy unexplained by loading conditions, with a maximal adult wall thickness of at least 15 mm (or at least 13 mm with a positive family history). It affects approximately 1 in 500 adults and is an important cause of sudden cardiac death, especially in young people. Roughly two-thirds of patients have left ventricular outflow tract obstruction at rest or with provocation, which is central to symptom management. Initial therapy for symptoms is beta-blockade (or a non-dihydropyridine calcium-channel blocker), with cardiac myosin inhibitors now an option for eligible obstructive disease and septal reduction reserved for drug-refractory obstruction. Implantable cardioverter-defibrillators are considered through shared decision-making based on validated risk factors, and atrial fibrillation warrants anticoagulation plus family screening of first-degree relatives.
Current evidence
Definition and diagnosis. HCM is defined by increased left ventricular wall thickness that cannot be explained solely by abnormal loading conditions; in adults the conventional threshold is a maximal end-diastolic wall thickness of at least 15 mm, or at least 13 mm when there is a known affected first-degree relative. Imaging must also exclude phenocopies such as hypertensive remodeling, aortic stenosis, infiltrative disease (for example amyloidosis), and athlete's heart. The 2024 AHA/ACC guideline emphasizes multiparametric evaluation with ECG, echocardiography, cardiac magnetic resonance imaging when needed, and genetic assessment. Epidemiology and genetics. HCM is reported worldwide and is one of the most common inherited heart diseases, with an estimated prevalence of about 1 in 500 adults. Pathogenic or likely pathogenic variants in sarcomere genes are identified in a substantial minority of probands, more often when there is familial disease, and genetic testing enables cascade screening. First-degree relatives should undergo ECG and echocardiographic screening, with genetic testing and counseling offered as appropriate. Pathophysiology and obstruction. Dynamic left ventricular outflow tract obstruction, defined as a peak gradient of at least 30 mm Hg at rest or with provocation, is present in roughly two-thirds of patients and results from septal hypertrophy, systolic anterior motion of the mitral valve, and flow drag. Many patients also have diastolic dysfunction, mitral regurgitation, myocardial ischemia, and a small ventricular cavity, which contribute to dyspnea, angina, palpitations, and syncope. Sudden cardiac death risk. Sudden cardiac death is the most feared complication, although absolute annual risk in unselected adults is generally around 0.5-1%. The 2024 AHA/ACC guideline uses a risk-factor approach, whereas the ESC HCM Risk-SCD model provides a quantitative estimate; both inform, but do not replace, shared decision-making about implantable cardioverter-defibrillators. Prior cardiac arrest or sustained ventricular tachycardia is a strong indication for an ICD. Pharmacotherapy and myosin inhibitors. Beta-blockers are first-line for symptomatic obstruction; non-dihydropyridine calcium-channel blockers and disopyramide are alternatives or add-ons. In EXPLORER-HCM, mavacamten improved exercise capacity and symptoms compared with placebo in obstructive HCM. In SEQUOIA-HCM, aficamten similarly improved peak oxygen uptake and symptoms at 24 weeks. Aficamten is FDA-approved for symptomatic obstructive HCM and requires echocardiographic monitoring under a risk evaluation and mitigation strategy because it can cause systolic dysfunction. Mavacamten is similarly FDA-approved for symptomatic obstructive HCM and requires echocardiographic monitoring under a risk evaluation and mitigation strategy. A 2025 randomized trial also reported benefit of mavacamten in symptomatic nonobstructive HCM, although this use is newer and not yet standard. Septal reduction and arrhythmia. For drug-refractory symptoms with obstruction, surgical myectomy is generally preferred at experienced centers, with alcohol septal ablation as an alternative when anatomy and patient factors are suitable. Atrial fibrillation affects a substantial proportion of patients, increases stroke risk, and generally warrants anticoagulation regardless of conventional stroke scores. Exercise, pregnancy, and screening. Moderate-intensity recreational exercise is generally encouraged rather than prohibited, with individual advice for competitive athletes. Most women with HCM tolerate pregnancy with multidisciplinary care, although risk is higher with severe obstruction or arrhythmia. Lifelong clinical follow-up is warranted because disease expression and risk can change.
Limitations
Several important uncertainties remain. The pivotal myosin-inhibitor trials were short (24-30 weeks), so effects on hard outcomes, disease progression, and long-term safety are still being defined. Risk-prediction models for sudden cardiac death are imperfect, and US and European guidelines weight risk factors differently, so ICD decisions remain preference-sensitive. Evidence is sparse for children, pregnancy, older adults, and many ancestral populations, and the optimal use of myosin inhibitors in nonobstructive disease is still evolving. Access and cost can limit uptake, and this summary is a general educational synthesis rather than a systematic review or individualized medical advice.
What this means
Clinical practice should start with confirming the phenotype and excluding mimics, then characterizing obstruction and sudden-death risk before choosing therapy. Patients with symptoms and obstruction should be managed at or in partnership with an HCM center, especially when myosin inhibitors or septal reduction are being considered. Family members should receive cascade ECG and echocardiographic screening, and genetic counseling should be offered when a pathogenic variant is found. Health systems should support reliable echocardiographic monitoring for patients starting cardiac myosin inhibitors. Multidisciplinary clinics, affordable access, and longer-term registries are also needed.
EvidenceSources (8)
Last checked 2026-10-22Source details
Sources (8)
Confidence is an AI estimate, not an independent assessment of source quality.
- 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy
Ommen SR, Ho CY, Asif IM, et al.; American Heart Association/American College of Cardiology · 2024-05-08
GuidelineAI confidence: 99% - Nonsyndromic Hypertrophic Cardiomyopathy Overview
Cirino AL, Channaoui N, Ho C; GeneReviews · 2025-03-06
Peer reviewedAI confidence: 93% - 2023 ESC Guidelines for the management of cardiomyopathies
Arbelo E, Protonotarios A, Gimeno JR, et al.; ESC Scientific Document Group · 2023-10-01
GuidelineAI confidence: 98% - Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial
Olivotto I, Oreziak A, Barriales-Villa R, et al. · 2020-09-01
Peer reviewedAI confidence: 98% - Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy
Maron MS, Masri A, Nassif ME, et al. · 2024-05-30
Peer reviewedAI confidence: 98% - FDA approves drug to improve functional capacity and symptoms in adults with rare inherited heart condition
U.S. Food and Drug Administration · 2025-12-23
Reputable websiteAI confidence: 97% - FDA approves new drug to improve heart function in adults with rare heart condition
U.S. Food and Drug Administration · 2022-04-29
Reputable websiteAI confidence: 97% - Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy
Desai MY, Owens AT, Abraham TP, et al. · 2025-09-11
Peer reviewedAI confidence: 95%
Update history
- Initial answerVersion 1Initial evidence summary on hypertrophic cardiomyopathy, covering definition, diagnosis, risk stratification, myosin inhibitors, septal reduction, and family screening.8 sources · AI-generated